Stickler Syndrome Clinical Trials and Treatments

Stickler syndrome is a rare autosomal dominant connective tissue disorder caused by mutations in genes encoding type II collagen or related proteins (primarily COL2A1, COL11A1, COL11A2, and other genes affecting extracellular matrix). The underlying defect affects structural proteins essential for tissues requiring significant mechanical strength and flexibility including the eyes, joints, and ears. Ocular manifestations are prominent and often the presenting feature, including high myopia (often >-3 diopters), vitreous abnormalities (liquefaction, opacification, floaters), retinal detachment risk (occurring in 40-50% of untreated patients), and progressive cataracts.

The most common symptoms of Stickler Syndrome include Severe myopia and vision problems, Vitreous floaters and liquefaction, Progressive joint disease and arthritis, Sensorineural hearing loss, Cleft palate in some cases, among others. Stickler Syndrome affects approximately 1 in 7,500 to 9,500 people. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Stickler Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Clinical trials are investigating therapies targeting collagen dysfunction, inflammatory pathways, and compensatory mechanisms in joint disease progression. Early ophthalmology intervention including corrective lenses, contact lenses for high myopia, and regular retinal monitoring prevents vision loss and detachment.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Stickler Syndrome. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

Stickler Syndrome is caused by variants in the COL2A1, COL11A1, COL11A2, COL9A1, COL9A2 and COL9A3 genes. About 80% of cases are COL2A1.

It follows autosomal dominant (COL2A1, COL11A1, COL11A2) or autosomal recessive (COL9A1, COL9A2, COL9A3) inheritance. The condition affects approximately 1 in 7,500 to 9,500 people. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Stickler Syndrome looks at the COL2A1, COL11A1, COL11A2, COL9A1, COL9A2 and COL9A3 genes. About 80% of cases are COL2A1.

It follows autosomal dominant (COL2A1, COL11A1, COL11A2) or autosomal recessive (COL9A1, COL9A2, COL9A3) inheritance.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Stickler Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Stickler Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.